PharmTech spoke with Tara Dougal, event director for pharma at Informa Markets, about trends impacting the pharmaceutical industry and how CPHI Milan is addressing these areas this year.
|Articles|August 1, 2011
Pharmaceutical Technology Europe
- Pharmaceutical Technology Europe-08-01-2011
- Volume 23
- Issue 8
Improving API Synthesis
Author(s)Patricia Van Arnum
O-arylation and O-alkylation, a one-pot protein synthesis, a combined approach in continued and chemocatalysis, and green-chemistry applications are the target of some recent advances in API synthesis.
Advertisement
By Patricia Van Arnum
O-arylation and O-alkylation, a one-pot protein synthesis, a combined approach in continued and chemocatalysis, and green-chemistry applications are the target of some recent advances in API synthesis.
This article was also published in our US sister publication Pharmaceutical Technology and can be read
Articles in this issue
about 15 years ago
Understanding Fluidized-Bed Granulationabout 15 years ago
Controlled Release from Porous Platformsabout 15 years ago
Controlled Crystallization During Freeze-Dryingabout 15 years ago
Movin' On Outabout 15 years ago
The Many Varieties Of 'Emerging'about 15 years ago
Newsabout 15 years ago
Managing Information Overloadabout 15 years ago
The Importance Of Filter Testingabout 15 years ago
Making A Mark In Emerging Marketsabout 15 years ago
Croatia, Pharma and CorruptionAdvertisement
Related to this article
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Karthik Iyer, Eli Lilly, details an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
Advertisement
Advertisement